Erythropoietin and the cardiorenal syndrome: Cellular mechanisms on the cardiorenal connectors

American Journal of Physiology - Renal Physiology

Volumn 291, Issue 5, 2006, Pages

  Jie, Kim E ^a   Verhaar, Marianne C ^a   Cramer, Maarten Jan M ^a   Van Der Putten, Karien ^b   Gaillard, Carlo A J M ^b   Doevendans, Pieter A ^a   Koomans, Hein A ^a   Joles, Jaap A ^a   Braam, Branko ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b MEANDER MEDICAL CENTER   (Netherlands)

Author keywords

Anemia; Heart failure; Nitric oxide; Reactive oxygen species; Renal failure

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; DIURETIC AGENT; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE;

ADRENERGIC SYSTEM; ANEMIA; APOPTOSIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CRUSH SYNDROME; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ERYTHROID PRECURSOR CELL; HEART FAILURE; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; INFLAMMATION; KIDNEY FAILURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; ANIMAL; CHRONIC KIDNEY FAILURE; CONGESTIVE HEART FAILURE; METABOLISM; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ERYTHROPOIETIN; HEART FAILURE, CONGESTIVE; HUMANS; KIDNEY FAILURE, CHRONIC; OXIDATIVE STRESS;

EID: 33750957845     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00200.2006     Document Type: Review

References (183)

1. Acs G, Zhang PJ, Rebbeck TR, Acs P, and Verma A. Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer 95: 969-981, 2002.
2. Agnello D, Bigini P, Villa P, Mennini T, Cerami A, Brines ML, and Ghezzi P. Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res 952: 128-134, 2002.
3. 2+ mobilization in cultured rat vascular smooth-muscle cells. Nephrol Dial Transplant 16: 491-499, 2001.
4. Akimoto T, Kusano E, Inaba T, Iimura O, Takahashi H, Ikeda H, Ito C, Ando Y, Ozawa K, and Asano Y. Erythropoietin regulates vascular smooth muscle cell apoptosis by a phosphatidylinositol 3 kinase-dependent pathway. Kidney Int 58: 269-282, 2000.
5. Alexander WS, Starr R, Fenner JE, Scott CL, Handman E, Sprigg NS, Corbin JE, Cornish AL, Darwiche R, Owczarek CM, Kay TW, Nicola NA, Hertzog PJ, Metcalf D, and Hilton DJ. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 98: 597-608, 1999.
6. Allen DA, Breen C, Yaqoob MM, and Macdougall IC. Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: role of IFN-gamma and TNF-alpha. J Investig Med 47: 204-211, 1999.
7. Ammarguellat F, Gogusev J, and Drueke TB. Direct effect of erythropoietin on rat vascular smooth muscle cell via a putative erythropoietin receptor. Nephrol Dial Transplant 11: 687-692, 1996.
8. Anagnostou A, Lee ES, Kessimian N, Levinson R, and Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 87: 5978-5982, 1990.
9. Bagnis C, Beaufils H, Jacquiaud C, Adabra Y, Jouanneau C, Le Nahour G, Jaudon MC, Bourbouze R, Jacobs C, and Deray G. Erythropoietin enhances recovery after cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant 16: 932-938, 2001.
10. Bahlmann FH, DeGroot K, Duckert T, Niemczyk E, Bahlmann E, Boehm SM, Haller H, and Fliser D. Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int 64: 1648-1652, 2003.
11. Banerjee D, Rodriguez M, Nag M, and Adamson JW. Exposure of endothelial cells to recombinant human erythropoietin induces nitric oxide synthase activity. Kidney Int 57: 1895-1904, 2000.
12. Barany P, Divino Filho JC, and Bergstrom J. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis 29: 565-568, 1997.
13. Barrett JD, Zhang Z, Zhu JH, Lee DB, Ward HJ, Jamgotchian N, Hu MS, Fredal A, Giordani M, and Eggena P. Erythropoietin upregulates angiotensin receptors in cultured rat vascular smooth muscle cells. J Hypertens 16: 1749-1757, 1998.
14. Beleslin-Cokic BB, Cokic VP, Yu X, Weksler BB, Schechter AN, and Noguchi CT. Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood 104: 2073-2080, 2004.
15. Bernaudin M, Marti HH, Roussel S, Divoux D, Nouvelot A, MacKenzie ET, and Petit E. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 19: 643-651, 1999.
16. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, and Goodkin DA. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584-590, 1998.
17. Bhat GJ, Abraham ST, and Baker KM. Angiotensin II interferes with interleukin 6-induced Stat3 signaling by a pathway involving mitogen-activated protein kinase kinase 1. J Biol Chem 271: 22447-22452, 1996.
18. Biaggioni I, Robertson D, Krantz S, Jones M, and Haile V. The anemia of primary autonomic failure and its reversal with recombinant erythropoietin. Ann Intern Med 121: 181-186, 1994.
19. Bongartz LG, Cramer MJ, and Braam B. The cardiorenal connection (Abstract). Hypertension 43: e14, 2004.
20. Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, and Braam B. The severe cardiorenal syndrome: 'Guyton revisited'. Eur Heart J 26: 11-17, 2005.
21. Boo YC and Jo H. Flow-dependent regulation of endothelial nitric oxide synthase: role of protein kinases. Am J Physiol Cell Physiol 285: C499-C508, 2003.
22. Buemi M, Denuzzo G, Allegra A, Aloisi C, Squadrito F, Squadrito G, Dattola A, Corica F, and Vermiglio G. Recombinant human erythropoietin inhibits the cutaneous vasodilatation induced by acetylcholine. Int J Microcirc Clin Exp 15: 283-286, 1995.
23. Calo LA, Stanic L, Davis PA, Pagnin E, Munaretto G, Fusaro M, Landini S, Semplicini A, and Piccoli A. Effect of epoetin on HO-1 mRNA level and plasma antioxidants in hemodialysis patients. Int J Clin Pharmacol Ther 41: 187-192, 2003.
24. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A, and Brines M. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 100: 4802-4806, 2003.
25. Caravaca F, Pizarro JL, Arrobas M, Cubero JJ, Garcia MC, and Perez-Miranda M. Antiplatelet therapy and development of hypertension induced by recombinant human erythropoietin in uremic patients. Kidney Int 45: 845-851, 1994.
26. Carlini RG, Alonzo EJ, Dominguez J, Blanca I, Weisinger JR, Rothstein M, and Bellorin-Font E. Effect of recombinant human erythropoietin on endothelial cell apoptosis. Kidney Int 55: 546-553, 1999.
27. Carlini RG, Dusso AS, Obialo CI, Alvarez UM, and Rothstein M. Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. Kidney Int 43: 1010-1014, 1993.
28. Carlini RG, Reyes AA, and Rothstein M. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int 47: 740-745, 1995.
29. Chabrashvili T, Kitiyakara C, Blau J, Karber A, Aslam S, Welch WJ, and Wilcox CS. Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am J Physiol Regul Integr Comp Physiol 285: R117-R124, 2003.
30. Chattopadhyay A, Choudhury TD, Bandyopadhyay D, and Datta AG. Protective effect of erythropoietin on the oxidative damage of erythrocyte membrane by hydroxyl radical. Biochem Pharmacol 59: 419-425, 2000.
31. Chin K, Oda N, Shen K, and Noguchi CT. Regulation of transcription of the human erythropoietin receptor gene by proteins binding to GATA-1 and Sp1 motifs. Nucleic Acids Res 23: 3041-3049, 1995.
32. Chong ZZ, Kang JQ, and Maiese K. Angiogenesis and plasticity: role of erythropoietin in vascular systems. J Hematother Stem Cell Res 11: 863-871, 2002.
33. Chong ZZ, Kang JQ, and Maiese K. Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades. J Cereb Blood Flow Metab 22: 503-514, 2002.
34. Choudhury TD, Das N, Chattopadhyay A, and Datta AG. Effect of oxidative stress and erythropoietin on cytoskeletal protein and lipid organization in human erythrocytes. Pol J Pharmacol 51: 341-350, 1999.
35. Clark RA and Valente AJ. Nuclear factor kappa B activation by NADPH oxidases. Mech Ageing Dev 125: 799-810, 2004.
36. Collins AJ. Anaemia management prior to dialysis: cardiovascular and cost-benefit observations. Nephrol Dial Transplant 2: ii2-ii6, 2003.
37. Constantinescu SN, Ghaffari S, and Lodish HF. The erythropoietin receptor: structure, activation and intracellular signal transduction. Trends Endocrinol Metab 10: 18-23, 1999.
38. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, and Victor RG. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 327: 1912-1918, 1992.
39. Corti MC, Guralnik JM, Salive ME, Ferrucci L, Pahor M, Wallace RB, and Hennekens CH. Serum iron level, coronary artery disease, and all-cause mortality in older men and women. Am J Cardiol 79: 120-127, 1997.
40. Cuzzocrea S, Mazzon E, di Paola R, Genovese T, Patel NS, Britti D, de Majo M, Caputi AP, and Thiemermann C. Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse. Arthritis Rheum 52: 940-950, 2005.
41. De Groot K, Bahlmann FH, Sowa J, Koenig J, Menne J, Haller H, and Fliser D. Uremia causes endothelial progenitor cell deficiency. Kidney Int 66: 641-646, 2004.
42. Debska-Slizien A, Owczarzak A, Lysiak-Szydlowska W, and Rutkowski B. Erythrocyte metabolism during renal anemia treatment with recombinant human erythropoietin. Int J Artif Organs 27: 935-942, 2004.
43. Delmas-Beauvieux MC, Combe C, Peuchant E, Carbonneau MA, Dubourg L, de Precigout V, Aparicio M, and Clerc M. Evaluation of red blood cell lipoperoxidation in hemodialysed patients during erythropoietin therapy supplemented or not with iron. Nephron 69: 404-410, 1995.
44. Dries DL, Exner DV, Domanski MJ, Greenberg B, and Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 35: 681-689, 2000.
45. Ebert BL and Bunn HF. Regulation of the erythropoietin gene. Blood 94: 1864-1877, 1999.
46. Echigoya MH, Obikane K, Nakashima T, and Sasaki S. Glomerular localization of erythropoietin receptor mRNA and protein in neonatal and mature mouse kidney. Nephron Exp Nephrol 100: e21-e29, 2005.
47. Emir M, Ozisik K, Cagli K, Misirlioglu M, Ozisik P, Iscan Z, Yildirim E, Kilinc K, and Sener E. Effect of erythropoietin on bcl-2 gene expression in rat cardiac myocytes after traumatic brain injury. Transplant Proc 36: 2935-2938, 2004.
48. Erbayraktar S, Yilmaz O, Gokmen N, and Brines M. Erythropoietin is a multifunctional tissue-protective cytokine. Curr Hematol Rep 2: 465-470, 2003.
49. Fandrey J and Bunn HF. In vivo and in vitro regulation of erythropoietin mRNA: measurement by competitive polymerase chain reaction. Blood 81: 617-623, 1993.
50. Faquin WC, Schneider TJ, and Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 79: 1987-1994, 1992.
51. Farrell F and Lee A. The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist 9, Suppl 5: 18-30, 2004.
52. Felker GM, Adams KF Jr, Gattis WA, and O'Connor CM. Anemia as a risk factor and therapeutic target in heart failure. J Am Coll Cardiol 44: 959-966, 2004.
53. Figueroa YG, Chan AK, Ibrahim R, Tang Y, Burow ME, Alam J, Scandurro AB, and Beckman BS. NF-kappaB plays a key role in hypoxia-inducible factor-1-regulated erythropoietin gene expression. Exp Hematol 30: 1419-1427, 2002.
54. Fiordaliso F, Chimenti S, Staszewsky L, Bai A, Carlo E, Cuccovillo I, Doni M, Mengozzi M, Tonelli R, Ghezzi P, Coleman T, Brines M, Cerami A, and Latini R. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci USA 102: 2046-2051, 2005.
55. Fishbane S, Ragolia L, Palaia T, Johnson B, Elzein H, and Maesaka JK. Cytoprotection by darbepoetin/epoetin alpha in pig tubular and mouse mesangial cells. Kidney Int 65: 452-458, 2004.
56. Freudenthaler SM, Lucht I, Schenk T, Brink M, and Gleiter CH. Dose-dependent effect of angiotensin II on human erythropoietin production. Pflügers Arch 439: 838-844, 2000.
57. Freudenthaler SM, Schreeb K, Korner T, and Gleiter CH. Angiotensin II increases erythropoietin production in healthy human volunteers. Eur J Clin Invest 29: 816-823, 1999.
58. Fritschka E, Neumayer HH, Seddighi S, Thiede HM, Distler A, and Philipp T. Effect of erythropoietin on parameters of sympathetic nervous activity in patients undergoing chronic haemodialysis. Br J Clin Pharmacol 30, Suppl 1: 135S-138S, 1990.
59. George J, Goldstein E, Abashidze A, Wexler D, Hamed S, Shmilovich H, Deutsch V, Miller H, Keren G, and Roth A. Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner. Cardiovasc Res 68: 299-306, 2005.
60. Ghiadoni L, Cupisti A, Huang Y, Mattei P, Cardinal H, Favilla S, Rindi P, Barsotti G, Taddei S, and Salvetti A. Endothelial dysfunction and oxidative stress in chronic renal failure. J Nephrol 17: 512-519, 2004.
61. Gobert S, Duprez V, Lacombe C, Gisselbrecht S, and Mayeux P. The signal transduction pathway of erythropoietin involves three forms of mitogen-activated protein (MAP) kinase in UT7 erythroleukemia cells. Eur J Biochem 234: 75-83, 1995.
62. Goicoechea M, Martin J, de Sequera P, Quiroga JA, Ortiz A, Carreno V, and Caramelo C. Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney Int 54: 1337-1343, 1998.
63. Gorio A, Gokmen N, Erbayraktar S, Yilmaz O, Madaschi L, Cichetti C, Di Giulio AM, Vardar E, Cerami A, and Brines M. Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci USA 99: 9450-9455, 2002.
64. Griendling KK, Minieri CA, Ollerenshaw JD, and Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74: 1141-1148, 1994.
65. Guo Y, Mascareno E, and Siddiqui MA. Distinct components of Janus kinase/signal transducer and activator of transcription signaling pathway mediate the regulation of systemic and tissue localized renin-angiotensin system. Mol Endocrinol 18: 1033-1041, 2004.
66. Ha TK, Sattar N, Talwar D, Cooney J, Simpson K, O'Reilly DS, and Lean ME. Abnormal antioxidant vitamin and carotenoid status in chronic renal failure. QJM 89: 765-769, 1996.
67. Halliwell B and Gutteridge JMC. Free Radicals in Biology and Medicine. New York: Oxford Univ. Press, 1999.
68. Hand MF, Haynes WG, Johnstone HA, Anderton JL, and Webb DJ. Erythropoietin enhances vascular responsiveness to norepinephrine in renal failure. Kidney Int 48: 806-813, 1995.
69. Handelman GJ, Walter MF, Adhikarla R, Gross J, Dallal GE, Levin NW, and Blumberg JB. Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int 59: 1960-1966, 2001.
70. Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, Mildner-Rihm C, Martin H, Zeiher AM, and Dimmeler S. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102: 1340-1346, 2003.
71. Hernandez-Vargas P, Lopez-Franco O, Sanjuan G, Ruperez M, Ortiz-Munoz G, Suzuki Y, Aguado-Roncero P, Perez-Tejerizo G, Blanco J, Egido J, Ruiz-Ortega M, and Gomez-Guerrero C. Suppressors of cytokine signaling regulate angiotensin II-activated Janus kinase-signal transducers and activators of transcription pathway in renal cells. J Am Soc Nephrol 16: 1673-1683, 2005.
72. Hillege HL, Girbes AR, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, Hampton JR, and van Veldhuisen DJ. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 102: 203-210, 2000.
73. Hirota H, Yoshida K, Kishimoto T, and Taga T. Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci USA 92: 4862-4866, 1995.
74. Horl WH and Ertl G. Anaemia and the heart. Eur J Clin Invest 35, Suppl 3: 20-25, 2005.
75. Horl WH, Jacobs C, Macdougall IC, Valderrabano F, Parrondo I, Thompson K, and Carveth BG. European best practice guidelines 14-16: inadequate response to epoetin. Nephrol Dial Transplant 15, Suppl 4: 43-50, 2000.
76. Huang LE, Willmore WG, Gu J, Goldberg MA, and Bunn HF. Inhibition of hypoxia-inducible factor 1 activation by carbon monoxide and nitric oxide. Implications for oxygen sensing and signaling. J Biol Chem 274: 9038-9044, 1999.
77. Iiyama M, Kakihana K, Kurosu T, and Miura O. Reactive oxygen species generated by hematopoietic cytokines play roles in activation of receptor-mediated signaling and in cell cycle progression. Cell Signal 18: 174-182, 2006.
78. Imai Y, Sekino H, Fujikura Y, Munakata M, Minami N, Hashimoto J, Sakuma H, Watanabe N, Misawa S, and Nishiyama A. Pressor effect of recombinant human erythropoietin: results of ambulatory blood pressure monitoring and home blood pressure measurements. Clin Exp Hypertens 17: 485-506, 1995.
79. Inal M, Kanbak G, Sen S, Akyuz F, and Sunal E. Antioxidant status and lipid peroxidation in hemodialysis patients undergoing erythropoietin and erythropoietin-vitamin E combined therapy. Free Radic Res 31: 211-216, 1999.
80. Iwamoto T, Senga T, Naito Y, Matsuda S, Miyake Y, Yoshimura A, and Hamaguchi M. The JAK-inhibitor, JAB/SOCS-1 selectively inhibits cytokine-induced, but not v-Src induced JAK-STAT activation. Oncogene 19: 4795-4801, 2000.
81. Jandeleit K, Heintz B, Gross-Heitfeld E, Kindler J, Sieberth HG, Kirsten R, and Nelson K. Increased activity of the autonomic nervous system and increased sensitivity to angiotensin II infusion after therapy with recombinant human erythropoietin. Nephron 56: 220-221, 1990.
82. Jaquet K, Krause K, Tawakol-Khodai M, Geidel S, and Kuck KH. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 64: 326-333, 2002.
83. Jegalian AG and Wu H. Differential roles of SOCS family members in EpoR signal transduction. J Interferon Cytokine Res 22: 853-860, 2002.
84. Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol Rev 72: 449-489, 1992.
85. Jelkmann W. Molecular biology of erythropoietin. Intern Med 43: 649-659, 2004.
86. Jelkmann W. Renal erythropoietin: properties and production. Rev Physiol Biochem Pharmacol 104: 139-215, 1986.
87. Jelkmann W, Pagel H, Hellwig T, and Fandrey J. Effects of antioxidant vitamins on renal and hepatic erythropoietin production. Kidney Int 51: 497-501, 1997.
88. Jelkmann W, Pagel H, Wolff M, and Fandrey J. Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys. Life Sci 50: 301-308, 1992.
89. Juul SE, Yachnis AT, and Christensen RD. Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum Dev 52: 235-249, 1998.
90. Kanagy NL, Perrine MF, Cheung DK, and Walker BR. Erythropoietin administration in vivo increases vascular nitric oxide synthase expression. J Cardiovasc Pharmacol 42: 527-533, 2003.
91. Kaptanoglu E, Solaroglu I, Okutan O, Surucu HS, Akbiyik F, and Beskonakli E. Erythropoietin exerts neuroprotection after acute spinal cord injury in rats: effect on lipid peroxidation and early ultrastructural findings. Neurosurg Rev 27: 113-120, 2004.
92. Katoh M, Egashira K, Usui M, Ichiki T, Tomita H, Shimokawa H, Rakugi H, and Takeshita A. Cardiac angiotensin II receptors are upregulated by long-term inhibition of nitric oxide synthesis in rats. Circ Res 83: 743-751, 1998.
93. Kazmi WH, Kausz AT, Khan S, Abichandani R, Ruthazer R, Obrador GT, and Pereira BJ. Anemia: an early complication of chronic renal insufficiency. Am J Kidney Dis 38: 803-812, 2001.
94. Klingmuller U, Lorenz U, Cantley LC, Neel BG, and Lodish HF. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 80: 729-738, 1995.
95. Kodama H, Fukuda K, Pan J, Makino S, Sano M, Takahashi T, Hori S, and Ogawa S. Biphasic activation of the JAK/STAT pathway by angiotensin II in rat cardiomyocytes. Circ Res 82: 244-250, 1998.
96. Kokot F, Wiecek A, Schmidt-Gayk H, Marcinkowski W, Gilge U, Heidland A, Rudka R, and Trembecki J. Function of endocrine organs in hemodialyzed patients of long-term erythropoietin therapy. Artif Organs 19: 428-435, 1995.
97. Koomans HA, Blankestijn PJ, and Joles JA. Sympathetic hyperactivity in chronic renal failure: a wake-up call. J Am Soc Nephrol 15: 524-537, 2004.
98. Ksiazek A, Zaluska WT, and Ksiazek P. Effect of recombinant human erythropoietin on adrenergic activity in normotensive hemodialysis patients. Clin Nephrol 56: 104-110, 2001.
99. Kumral A, Gonenc S, Acikgoz O, Sonmez A, Genc K, Yilmaz O, Gokmen N, Duman N, and Ozkan H. Erythropoietin increases glutathione peroxidase enzyme activity and decreases lipid peroxidation levels in hypoxic-ischemic brain injury in neonatal rats. Biol Neonate 87: 15-18, 2004.
100. Kunisada K, Tone E, Fujio Y, Matsui H, Yamauchi-Takihara K, and Kishimoto T. Activation of gp130 transduces hypertrophic signals via STAT3 in cardiac myocytes. Circulation 98: 346-352, 1998.
101. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, and Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 77: 176-185, 1997.
102. Kusano E, Akimoto T, Inoue M, Masunaga Y, Umino T, Ono S, Ando Y, Homma S, Muto S, Komatsu N, and Asano Y. Human recombinant erythropoietin inhibits interleukin-1beta-stimulated nitric oxide and cyclic guanosine monophosphate production in cultured rat vascular smooth-muscle cells. Nephrol Dial Transplant 14: 597-603, 1999.
103. La Ferla K, Reimann C, Jelkmann W, and Hellwig-Burgel T. Inhibition of erythropoietin gene expression signaling involves the transcription factors GATA-2 and NF-κB. FASEB J 16: 1811-1813, 2002.
104. Larsen L and Ropke C. Suppressors of cytokine signalling: SOCS. APMIS 110: 833-844, 2002.
105. Liao J, Keiser JA, Scales WE, Kunkel SL, and Kluger MJ. Role of epinephrine in TNF and IL-6 production from isolated perfused rat liver. Am J Physiol Regul Integr Comp Physiol 268: R896-R901, 1995.
106. Ludat K, Sommerburg O, Grune T, Siems WG, Riedel E, and Hampl H. Oxidation parameters in complete correction of renal anemia. Clin Nephrol 53: S30-35, 2000.
107. Luo G and Yu-Lee L. Stat5b inhibits NFkappaB-mediated signaling. Mol Endocrinol 14: 114-123, 2000.
108. Macdougall IC. Could anti-inflammatory cytokine therapy improve poor treatment outcomes in dialysis patients? Nephrol Dial Transplant 19, Suppl 5: V73-V78, 2004.
109. Macdougall IC and Cooper A. The inflammatory response and epoetin sensitivity. Nephrol Dial Transplant 17, Suppl 1: 48-52, 2002.
110. Maiese K, Li F, and Chong ZZ. New avenues of exploration for erythropoietin. JAMA 293: 90-95, 2005.
111. Marine JC, McKay C, Wang D, Topham DJ, Parganas E, Nakajima H, Pendeville H, Yasukawa H, Sasaki A, Yoshimura A, and Ihle JN. SOCS3 is essential in the regulation of fetal liver erythropoiesis. Cell 98: 617-627, 1999.
112. 1 receptor. Nature 375: 247-250, 1995.
113. 2+ channels: activation by phospholipase C-gamma 1. Kidney Int 53: 1259-1268, 1998.
114. Maschio G. Erythropoietin and systemic hypertension. Nephrol Dial Transplant 10, Suppl 2: 74-79, 1995.
115. Migliaccio AR, Jiang Y, Migliaccio G, Nicolis S, Crotta S, Ronchi A, Ottolenghi S, and Adamson JW. Transcriptional and posttranscriptional regulation of the expression of the erythropoietin receptor gene in human erythropoietin-responsive cell lines. Blood 82: 3760-3769, 1993.
116. Mimic-Oka J, Simic T, and Djukanovic L. Epoetin treatment improves red blood cell and plasma antioxidant capacity in hemodialysis patients. Ren Fail 24: 77-87, 2002.
117. Miura Y, Miura O, Ihle JN, and Aoki N. Activation of the mitogen-activated protein kinase pathway by the erythropoietin receptor. J Biol Chem 269: 29962-29969, 1994.
118. Muegge K, Williams TM, Kant J, Karin M, Chiu R, Schmidt A, Siebenlist U, Young HA, and Durum SK. Interleukin-1 costimulatory activity on the interleukin-2 promoter via AP-1. Science 246: 249-251, 1989.
119. Muller R, Steffen HM, Brunner R, Pollok M, Baldamus CA, and Kaufmann W. Disordered alpha 2-adrenoreceptor function in hemodialysis patients with renal anemia-a possible cause of increased blood pressure in relation to recombinant human erythropoietin? Klin Wochenschr 69: 742-748, 1991.
120. Muntner P, He J, Hamm L, Loria C, and Whelton PK. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 13: 745-753, 2002.
121. Neusser M, Tepel M, and Zidek W. Erythropoietin increases cytosolic free calcium concentration in vascular smooth muscle cells. Cardiovasc Res 27: 1233-1236, 1993.
122. Niijima A, Hori T, Aou S, and Oomura Y. The effects of interleukin-1 beta on the activity of adrenal, splenic and renal sympathetic nerves in the rat. J Auton Nerv Syst 36: 183-192, 1991.
123. Ogilvie M, Yu X, Nicolas-Metral V, Pulido SM, Liu C, Ruegg UT, and Noguchi CT. Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts. J Biol Chem 275: 39754-39761, 2000.
124. Okura Y, Oshima T, Yasunobu Y, Amano K, Mori M, Shinozaki K, and Kajiyama G. Effect of erythropoietin treatment on blood pressure and intracellular cation concentrations in maintenance hemodialysis patients. Hypertens Res 19: 91-95, 1996.
125. Ono K and Hisasue Y. The rate of increase in hematocrit, humoral vasoactive substances and blood pressure changes in hemodialysis patients treated with recombinant human erythropoietin or blood transfusion. Clin Nephrol 37: 23-27, 1992.
126. Onoyama K, Hori K, Osato S, and Fujishima M. Haemodynamic effect of recombinant human erythropoietin on hypotensive haemodialysis patients. Nephrol Dial Transplant 6: 562-565, 1991.
127. Papavasiliou EC, Gouva C, Siamopoulos KC, and Tselepis AD. Erythrocyte PAF-acetylhydrolase activity in various stages of chronic kidney disease: effect of long-term therapy with erythropoietin. Kidney Int 68: 246-255, 2005.
128. Parsa CJ, Kim J, Riel RU, Pascal LS, Thompson RB, Petrofski JA, Matsumoto A, Stamler JS, and Koch WJ. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J Biol Chem 279: 20655-20662, 2004.
129. Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, Thompson RB, Petrofski JA, Annex BH, Stamler JS, and Koch WJ. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112: 999-1007, 2003.
130. Portoles J, Torralbo A, Martin P, Rodrigo J, Herrero JA, and Barrientos A. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 29: 541-548, 1997.
131. Pratt MC, Lewis-Barned NJ, Walker RJ, Bailey RR, Shand BI, and Livesey J. Effect of angiotensin converting enzyme inhibitors on erythropoietin concentrations in healthy volunteers. Br J Clin Pharmacol 34: 363-365, 1992.
132. Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal JF, and Michel JB. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol 20: 645-651, 2000.
133. Ratajczak J, Majka M, Kijowski J, Baj M, Pan ZK, Marquez LA, Janowska-Wieczorek A, and Ratajczak MZ. Biological significance of MAPK, AKT and JAK-STAT protein activation by various erythropoietic factors in normal human early erythroid cells. Br J Haematol 115: 195-204, 2001.
134. Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell'Era P, Nico B, Roncali L, and Dammacco F. Human erythropoietin induces a proangiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 93: 2627-2636, 1999.
135. Robertson D, Krantz SB, and Biaggioni I. The anemia of microgravity and recumbency: role of sympathetic neural control of erythropoietin production. Acta Astronaut 33: 137-141, 1994.
136. Roger SD, Baker LR, and Raine AE. Autonomic dysfunction and the development of hypertension in patients treated with recombinant human erythropoietin (r-HuEPO). Clin Nephrol 39: 103-110, 1993.
137. Rui T, Feng Q, Lei M, Peng T, Zhang J, Xu M, Abel ED, Xenocostas A, and Kvietys PR. Erythropoietin prevents the acute myocardial inflammatory response induced by ischemia/reperfusion via induction of AP-1. Cardiovasc Res 65: 719-727, 2005.
138. Ruiz-Ortega M, Lorenzo O, and Egido J. Angiotensin III increases MCP-1 and activates NF-kappaB and AP-1 in cultured mesangial and mononuclear cells. Kidney Int 57: 2285-2298, 2000.
139. Sae-Ung N, Matsushima T, Choi I, Abe Y, Winichagoon P, Fucharoen S, Nawata H, and Muta K. Role of NF-kappa B in regulation of apoptosis of erythroid progenitor cells. Eur J Haematol 74: 315-323, 2005.
140. Scalera F, Kielstein JT, Martens-Lobenhoffer J, Postel SC, Tager M, and Bode-Boger SM. Erythropoietin increases asymmetric dimethylarginine in endothelial cells: role of dimethylarginine dimethylaminohydrolase. J Am Soc Nephrol 16: 892-898, 2005.
141. Schieffer B, Luchtefeld M, Braun S, Hilfiker A, Hilfiker-Kleiner D, and Drexler H. Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction. Circ Res 87: 1195-1201, 2000.
142. Schiffl H. Correlation of blood pressure in end-stage renal disease with platelet cytosolic free calcium concentration during treatment of renal anemia with recombinant human erythropoietin. Int J Artif Organs 15: 343-348, 1992.
143. Schmitz J, Weissenbach M, Haan S, Heinrich PC, and Schaper F. SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130. J Biol Chem 275: 12848-12856, 2000.
144. Schwarz H, Villiger PM, von Kempis J, and Lotz M. Neuropeptide Y is an inducible gene in the human immune system. J Neuroimmunol 51: 53-61, 1994.
145. Sengolge G, Horl WH, and Sunder-Plassmann G. Intravenous iron therapy: well-tolerated, yet not harmless. Eur J Clin Invest 35, Suppl 3: 46-51, 2005.
146. Serfling E, Barthelmas R, Pfeuffer I, Schenk B, Zarius S, Swoboda R, Mercurio F, and Karin M. Ubiquitous and lymphocyte-specific factors are involved in the induction of the mouse interleukin 2 gene in T lymphocytes. EMBO J 8: 465-473, 1989.
147. Sharples EJ, Patel N, Brown P, Stewart K, Mota-Philipe H, Sheaff M, Kieswich J, Allen D, Harwood S, Raftery M, Thiemermann C, and Yaqoob MM. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 15: 2115-2124, 2004.
148. Shaulian E and Karin M. AP-1 in cell proliferation and survival. Oncogene 20: 2390-2400, 2001.
149. Silva M, Benito A, Sanz C, Prosper F, Ekhterae D, Nunez G, and Fernandez-Luna JL. Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines. J Biol Chem 274: 22165-22169, 1999.
150. Silva M, Grillot D, Benito A, Richard C, Nunez G, and Fernandez-Luna JL. Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood 88: 1576-1582, 1996.
151. Silverberg D, Wexler D, Blum M, Wollman Y, and Iaina A. The cardio-renal anaemia syndrome: does it exist? Nephrol Dial Transplant 18, Suppl 8: viii7-viii12, 2003.
152. Silverberg DS, Wexler D, Blum M, and Iaina A. The cardiorenal anemia syndrome: correcting anemia in patients with resistant congestive heart failure can improve both cardiac and renal function and reduce hospitalizations. Clin Nephrol 60, Suppl 1: S93-S102, 2003.
153. Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, Brosh D, Laniado S, Schwartz D, Yachnin T, Shapira I, Gavish D, Baruch R, Koifman B, Kaplan C, Steinbruch S, and Iaina A. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 35: 1737-1744, 2000.
154. Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, Schwartz D, Yachnin T, Steinbruch S, Shapira I, Laniado S, and Iaina A. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 37: 1775-1780, 2001.
155. Siren AL, Fratelli M, Brines M, Goemans C, Casagrande S, Lewczuk P, Keenan S, Gleiter C, Pasquali C, Capobianco A, Mennini T, Heumann R, Cerami A, Ehrenreich H, and Ghezzi P. Erythropoietin prevents neuronal apoptosis after
156. Sitter T, Bergner A, and Schiffl H. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant 15: 1207-1211, 2000.
157. Smith KJ, Bleyer AJ, Little WC, and Sane DC. The cardiovascular effects of erythropoietin. Cardiovasc Res 59: 538-548, 2003.
158. Socolovsky M, Nam H, Fleming MD, Haase VH, Brugnara C, and Lodish HF. Ineffective erythropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts. Blood 98: 3261-3273, 2001.
159. Sommer U, Schmid C, Sobota RM, Lehmann U, Stevenson NJ, Johnston JA, Schaper F, Heinrich PC, and Haan S. Mechanisms of SOCS3 phosphorylation upon interleukin-6 stimulation. Contributions of Src- and receptor-tyrosine kinases. J Biol Chem 280: 31478-31488, 2005.
160. Spaia S, Pangalos M, Askepidis N, Pazarloglou M, Mavropoulou E, Theodoridis S, Dimitrakopoulos K, Milionis A, and Vayonas G. Effect of short-term rHuEPO treatment on insulin resistance in haemodialysis patients. Nephron 84: 320-325, 2000.
161. Strippoli GF, Craig JC, Manno C, and Schena FP. Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trials. J Am Soc Nephrol 15: 3154-3165, 2004.
162. Suliman HB, Ali M, and Piantadosi CA. Superoxide dismutase-3 promotes full expression of the EPO response to hypoxia. Blood 104: 43-50, 2004.
163. Tone E, Kunisada K, Fujio Y, Matsui H, Negoro S, Oh H, Kishimoto T, and Yamauchi-Takihara K. Angiotensin II interferes with leukemia inhibitory factor-induced STAT3 activation in cardiac myocytes. Biochem Biophys Res Commun 253: 147-150, 1998.
164. Vallance P, Leone A, Calver A, Collier J, and Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339: 572-575, 1992.
165. Van der Meer P, Voors AA, Lipsic E, Smilde TD, van Gilst WH, and van Veldhuisen DJ. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol 44: 63-67, 2004.
166. Vaziri ND. Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis 33: 821-828, 1999.
167. Vaziri ND, Ni Z, Wang XQ, Oveisi F, and Zhou XJ. Downregulation of nitric oxide synthase in chronic renal insufficiency: role of excess PTH. Am J Physiol Renal Physiol 274: F642-F649, 1998.
168. Vaziri ND, Zhou XJ, and Liao SY. Erythropoietin enhances recovery from cisplatin-induced acute renal failure. Am J Physiol Renal Fluid Electrolyte Physiol 266: F360-F366, 1994.
169. Vaziri ND, Zhou XJ, Naqvi F, Smith J, Oveisi F, Wang ZQ, and Purdy RE. Role of nitric oxide resistance in erythropoietin-induced hypertension in rats with chronic renal failure. Am J Physiol Endocrinol Metab 271: E113-E122, 1996.
170. Vesey DA, Cheung C, Pat B, Endre Z, Gobe G, and Johnson DW. Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant 19: 348-355, 2004.
171. Villa P, Bigini P, Mennini T, Agnello D, Laragione T, Cagnotto A, Viviani B, Marinovich M, Cerami A, Coleman TR, Brines M, and Ghezzi P. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 198: 971-975, 2003.
172. Wald MR, Borda ES, and Sterin-Borda L. Mitogenic effect of erythropoietin on neonatal rat cardiomyocytes: signal transduction pathways. J Cell Physiol 167: 461-468, 1996.
173. Wang XQ and Vaziri ND. Erythropoietin depresses nitric oxide synthase expression by human endothelial cells. Hypertension 33: 894-899, 1999.
174. Warren DJ and Ferris TF. Renin secretion in renal hypertension. Lancet 1: 159-162, 1970.
175. Westenfelder C, Biddle DL, and Baranowski RL. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int 55: 808-820, 1999.
176. Wickrema A, Krantz SB, Winkelmann JC, and Bondurant MC. Differentiation and erythropoietin receptor gene expression in human erythroid progenitor cells. Blood 80: 1940-1949, 1992.
177. Witko-Sarsat V, Friedlander M, Nguyen Khoa T, Capeillere-Blandin C, Nguyen AT, Canteloup S, Dayer JM, Jungers P, Drueke T, and Descamps-Latscha B. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 161: 2524-2532, 1998.
178. Wright GL, Hanlon P, Amin K, Steenbergen C, Murphy E, and Arcasoy MO. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J 18: 1031-1033, 2004.
179. Yang CW, Li C, Jung JY, Shin SJ, Choi BS, Lim SW, Sun BK, Kim YS, Kim J, Chang YS, and Bang BK. Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J 17: 1754-1755, 2003.
180. Yu X, Lin CS, Costantini F, and Noguchi CT. The human erythropoietin receptor gene rescues erythropoiesis and developmental defects in the erythropoietin receptor null mouse. Blood 98: 475-477, 2001.
181. Zaman K, Ryu H, Hall D, O'Donovan K, Lin KI, Miller MP, Marquis JC, Baraban JM, Semenza GL, and Ratan RR. Protection from oxidative stress-induced apoptosis in cortical neuronal cultures by iron chelators is associated with enhanced DNA binding of hypoxia-inducible factor-1 and ATF-1/CREB and increased expression of glycolytic enzymes, p21(waf1/cip1), and erythropoietin. J Neurosci 19: 9821-9830, 1999.
182. Zelko IN and Folz RJ. Extracellular superoxide dismutase functions as a major repressor of hypoxia-induced erythropoietin gene expression. Endocrinology 146: 332-340, 2005.
183. Zukowska-Grojec Z. Neuropeptide Y. A novel sympathetic stress hormone and more. Ann NY Acad Sci 771: 219-233, 1995.